Full Press Release Details
Pharmaceuticals Granted Approval to
of Its Oral Insulin Capsule
Designed to Evaluate Safety and Efficacy on
II Diabetic Volunteers
Israel - March 18, 2008 -- Oramed
Pharmaceuticals Inc. (OTCBB:ORMP, www.oramed.com) has been granted approval
the Institutional Review Board (IRB) committee of Hadassah Medical Center in
Jerusalem to conduct a Phase 2A study of its oral insulin on diabetic
volunteers. This Phase 2A study is designed to evaluate the safety and efficacy
of Oramed's oral insulin capsule on Type II diabetic volunteers.This study is
slated to begin in the second quarter of 2008. The trials are expected to last
oral insulin aims to revolutionize the current methods of treating diabetes,"
said Nadav Kidron, CEO of Oramed Pharmaceuticals. "An effective oral insulin
capsule would make insulin an earlier form of treatment for diabetes patients,
thereby allowing them to better control and balance their disease, leading
healthier overall condition."
Oramed Pharmaceuticals
Pharmaceuticals is an Israeli-based company focused on the development
delivery solutions based on proprietary technology. Diabetes is one of the
rapidly growing diseases in the world and is one that requires constant and
unpleasant monitoring and drug therapy regimens. Oramed is currently
an orally ingestible insulin capsule for the treatment of diabetes. The
is also pursuing the development of oral delivery solutions for other drugs
more information please visit our website at: www.oramed.com.
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties, and other factors which
may cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements
Pharmaceuticals, Inc
Granito, Steve Melfi